Synterex’s Post

For this month’s “Rare Disease of the Month,” Synterex is highlighting hereditary angioedema. This is a genetic disorder that is passed down through families. It causes fluids to collect outside of the blood vessels, leading to progressive swelling in tissues, particularly those in the hands, feet, limbs, face, intestinal tract, and airways. The swelling can look similar to hives but occurs under the skin and does not cause itching. Swelling in the intestinal tract can cause cramping, and swelling in the airways can make it hard to breathe—a potentially serious complication if not recognized and treated appropriately. These attacks gradually subside over 48 to 72 hours. Attacks can be triggered by dental procedures, sickness, stress, or surgery. Hereditary angioedema occurs when a protein called the C1 inhibitor is either absent or does not function properly. C1 inhibitor proteins are important for regulating the flow of body fluids into and out of cells. Although antihistamines and steroids are usually not effective in treating hereditary angioedema, there are several FDA-approved therapies that can help. Raising awareness for the disorder is important for ensuring that patients are treated appropriately in a timely manner. For more information on hereditary angioedema, you can visit: https://lnkd.in/gPe2pZ6A #RareDisease #HereditaryAngioedema #BeyondHAE

July 28 is World Hepatitis Day (WHD), which pays tribute to Dr. Baruch Blumberg (1925–2011), credited with the discovery of the hepatitis B virus in 1967. This discovery paved the way for the development of the first hepatitis B vaccine just 2 years later. His monumental contributions earned him the Nobel Prize in Physiology or Medicine in 1976. WHD serves as a global platform, endorsed by organizations like the World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC), to shed light on viral hepatitis, which affects over 354 million individuals worldwide. Viral hepatitis encompasses a cluster of infectious diseases, including hepatitis A, B, C, D, and E, that can lead to both acute and chronic liver ailments. With over one million deaths annually, viral hepatitis poses a significant public health challenge. Despite declines in fatalities from tuberculosis and HIV (human immunodeficiency virus), hepatitis-related deaths are on the rise. WHD offers an opportunity to raise awareness about the burden of these infections. To learn more about the CDC's initiatives in combating viral hepatitis globally, click here: https://lnkd.in/gewXB3S #WorldHepatitisDay #WHD #BaruchBlumberg

On July 27, 1921, Dr. Frederick Banting and Charles Best revolutionized diabetes treatment by successfully isolating insulin. Insulin is a hormone produced by specialized cells in the pancreas that helps regulate the amount of sugar in the blood. Their pioneering work involved isolating insulin from dogs, inducing diabetes symptoms in the animals, and then administering insulin injections to restore normal blood sugar levels. The journey from laboratory discovery to human application was swift. Insulin was extracted from the pancreases of cattle, and on January 11, 1922, Leonard Thompson, a 14-year-old boy with diabetes, received the first insulin injection. Initially, there were challenges, with the first dose causing an allergic reaction. However, the process was refined, and Thompson's second injection on January 23 proved successful, leading to a dramatic improvement in his condition. This breakthrough marked a paradigm shift in the management of diabetes, once considered a fatal disease. Insulin therapy offered newfound hope and a means of control for those living with diabetes. In 1923, Banting was awarded the Nobel Prize in Medicine along with Professor John Macleod, who contributed to the work. Although Charles Best, a crucial figure in the research, was not included in the Nobel Prize, Banting acknowledged his invaluable role by sharing the award money: https://lnkd.in/gauUHFvj #InsulinDiscovery #NobelPrize #MedicalMilestone

As a company, our roots are in clinical and regulatory consulting, but over the past several years, Synterex has demonstrated remarkable growth and expansion, including adding information technology (IT) services and collaboration solutions. Whether you need assistance with the transition to a fully mobile workplace, Office 365 or collaboration help, or employee training, our IT team is here for you. #Synterex #ITServices #MedicalWriting #MedTech

That’s a wrap! We connected with our fellow DOBEs this morning to discuss how to do business together. We were privileged to introduce an amazing session this morning about global procurement, sponsored by Ally Bank, which resonated with us as a global firm. We took away some concrete actions we can take to deepen our commitment to this community and share with our clients. We can’t wait for next year’s conference! #AreYouIN #DisabilityIN2024 #SynterexBusinessSolutions #SynterexSuccess

We have a dedicated Green Team to ensure we live out our values as a sustainable business. We monitor energy consumption, reduce waste, and develop policies and technologies that positively impact the planet—but there's always more we can do. What has been your company's biggest challenge in promoting green practices in the workplace? #Synterex #Sustainability

On Day 3 of Disability:IN's Global Annual Conference, we learned a lot about the economic impact of disability employment as well as job creation by DOBEs. It was a pleasure to hear a great story about connections in the disability community from the incomparable Fiona Dawson of Free Lion Productions. The session on AI, which was standing-room only, provided compelling examples of how technology has incredible potential to support the disability community when done right. It was nice to be in the hall watching this year (instead of competing!) for the DOBE pitch competition. All the pitches were amazing! We made some meaningful connections during the matchmaking portion as well as at the Disability Pride celebration in the evening. #AreYouIN #DisabilityIN2024 #SynterexBusinessSolutions #SynterexSuccess

Day 2 of Disability:IN's Global Annual Conference was packed with insights, from global business inclusion trends to the growing importance of publicly reporting disability data. Several sessions focused on business and capacity building for DOBEs. The session on accessibility leadership, innovation, and impact gave us tips we can share with our colleagues and clients. We also, of course, attended the Inclusion Awards ceremony, where we got to walk the stage, capping off the night with a visit to the bustling exhibit hall. #AreYouIN #DisabilityIN2024 #DisabilityConference #SynterexBusinessSolutions #SynterexSuccess

Synterex aims to uphold the highest standards of excellence in disability inclusion, so it's our honor to have been certified as a Disability:IN Disability-Owned Business Enterprise (DOBE) for the past three years. Here's to many more! #Synterex #DOBE #DisabilityOwned #DisabilityIN #DisabilityAwareness #Inclusion